Coherus BioSciences (CHRS) Reports In-Line Q4 EPS

Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($0.34), in-line with the analyst estimate of ($0.34). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $14.16 million.

For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.

You May Also Be Interested In

• Tesla readies August launch of CyberCab - The Information
• Eternity Founders Mohamad Al-Shami and Omar Abu Ghoush Announce US$1 Million Valuation
• SK Hynix (SKHY) call put ratio 1.1 calls to 1 put as share price up 2.6%